Anika Therapeutics (ANIK) Tops Q2 EPS by 13c

Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.57, $0.13 better than the analyst estimate of $0.44. Revenue for the quarter came in at $26.6 million versus the consensus estimate of $24.75 million.

“We continued our strong momentum in the second quarter, with total revenue growth of 16% year- over-year for the quarter,” said Charles H. Sherwood, Ph.D., President and Chief Executive Officer. “MONOVISC end user demand remained strong, we achieved important milestones in our global expansion with the launch of CINGAL in Canada and Europe, and we continued to advance our deep and differentiated pipeline. We are well-positioned to drive future growth and create significant near- and long-term value for patients and shareholders.”

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Huazhu Group Limited (HTHT) Tops Q2 EPS by 37c
• INVO Fertility (IVF) Tops Q2 EPS by 105c